ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p3.xmlSurviving the Perfect Storm: An RVU-Based Model to Evaluate the Continuing Impact of MMA on the Practice of Oncology2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p3.pdf2026-04-18Surviving the Perfect Storm: An RVU-Based Model to Evaluate the Continuing Impact of MMA on the Practice of Oncologyhttps://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p1.xmlWhere Are We Headed: The Value of Updating Guidelines2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p1.pdf2026-04-18Where Are We Headed: The Value of Updating Guidelineshttps://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p2.xmlThe CMS 2006 Quality in Oncology Demonstration Project and NCCN Guidelines2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p2.pdf2026-04-18The CMS 2006 Quality in Oncology Demonstration Project and NCCN Guidelineshttps://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p78.xmlDevelopmental Therapeutics for Myelodysplastic Syndromes2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p78.pdf2026-04-18Developmental Therapeutics for Myelodysplastic Syndromeshttps://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p37.xmlStrategies for the Treatment of Acute Promyelocytic Leukemia2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p37.pdf2026-04-18Strategies for the Treatment of Acute Promyelocytic Leukemiahttps://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p51.xmlNon-Transplant Therapy for Older Adults with Acute Myeloid Leukemia2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p51.pdf2026-04-18Non-Transplant Therapy for Older Adults with Acute Myeloid Leukemiahttps://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p58.xmlMyelodysplastic Syndromes Clinical Practice Guidelines in Oncology2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p16.xmlAcute Myeloid Leukemia Clinical Practice Guidelines in Oncology2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p91.xmlMyelodysplastic Syndromes: Iron Overload Consequences and Current Chelating Therapies2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p91.pdf2026-04-18Myelodysplastic Syndromes: Iron Overload Consequences and Current Chelating Therapieshttps://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p83.xmlSix (or More) Drugs in Search of a Mechanism: DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/4/1/article-p83.pdf2026-04-18Six (or More) Drugs in Search of a Mechanism: DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes